WallStreetZenWallStreetZen

NYSE: BIO
BIO-RAD LABORATORIES INC Stock Forecast, Predictions & Price Target

Analyst price target for BIO

Based on 1 analyst offering 12 month price targets for BIO-RAD LABORATORIES INC.
Min Forecast
$930.00+77.71%
Avg Forecast
$930.00+77.71%
Max Forecast
$930.00+77.71%

Should I buy or sell BIO stock?

Based on 1 analyst offering ratings for BIO-RAD LABORATORIES INC.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

BIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Wells Fargo
Top 7%
94
Strong BuyMaintains$930.00+77.71%2021-07-30

1 of 1

Forecast return on equity

Is BIO forecast to generate an efficient return?
Company
5.25%
Industry
22.38%
Market
39.88%
BIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIO forecast to generate an efficient return on assets?
Company
3.72%
Industry
11.49%
BIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIO earnings per share forecast

What is BIO's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.20
Avg 2 year Forecast
$15.65
Avg 3 year Forecast
$17.87

BIO revenue forecast

What is BIO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.9B-1.27%
Avg 2 year Forecast
$3.1B+6.13%
Avg 3 year Forecast
$3.3B+14.09%
BIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIO revenue growth forecast

How is BIO forecast to perform vs Medical Devices companies and vs the US market?
Company
3.11%
Industry
6.49%
Market
8.44%
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BIO$523.32$930.00+77.71%Strong Buy
SNN$31.55$37.00+17.27%Buy
PODD$194.74$289.44+48.63%Strong Buy
ABMD$238.65$338.33+41.77%Buy
ALGN$273.89$570.00+108.11%Strong Buy

BIO-RAD LABORATORIES Stock Forecast FAQ

Is BIO-RAD LABORATORIES Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: BIO) stock is to Strong Buy BIO stock.

Out of 1 analyst, 1 (100%) are recommending BIO as a Strong Buy, 0 (0%) are recommending BIO as a Buy, 0 (0%) are recommending BIO as a Hold, 0 (0%) are recommending BIO as a Sell, and 0 (0%) are recommending BIO as a Strong Sell.

What is BIO's earnings growth forecast for 2022-2024?

(NYSE: BIO) BIO-RAD LABORATORIES's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.61%.

BIO-RAD LABORATORIES's earnings in 2022 is -$101,125,000.On average, 1 Wall Street analyst forecast BIO's earnings for 2022 to be $425,170,805, with the lowest BIO earnings forecast at $425,170,805, and the highest BIO earnings forecast at $425,170,805. On average, 1 Wall Street analyst forecast BIO's earnings for 2023 to be $468,586,134, with the lowest BIO earnings forecast at $468,586,134, and the highest BIO earnings forecast at $468,586,134.

In 2024, BIO is forecast to generate $535,056,499 in earnings, with the lowest earnings forecast at $535,056,499 and the highest earnings forecast at $535,056,499.

What is BIO's revenue growth forecast for 2022-2024?

(NYSE: BIO) BIO-RAD LABORATORIES's forecast annual revenue growth rate of 3.11% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.44%.

BIO-RAD LABORATORIES's revenue in 2022 is $2,895,811,000.On average, 1 Wall Street analysts forecast BIO's revenue for 2022 to be $85,600,057,393, with the lowest BIO revenue forecast at $85,600,057,393, and the highest BIO revenue forecast at $85,600,057,393. On average, 1 Wall Street analysts forecast BIO's revenue for 2023 to be $92,019,537,720, with the lowest BIO revenue forecast at $92,019,537,720, and the highest BIO revenue forecast at $92,019,537,720.

In 2024, BIO is forecast to generate $98,921,077,903 in revenue, with the lowest revenue forecast at $98,921,077,903 and the highest revenue forecast at $98,921,077,903.

What is BIO's forecast return on assets (ROA) for 2022-2024?

(NYSE: BIO) forecast ROA is 3.72%, which is lower than the forecast US Medical Devices industry average of 11.49%.

What is BIO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BIO price target, the average BIO price target is $930.00, with the highest BIO stock price forecast at $930.00 and the lowest BIO stock price forecast at $930.00.

The Wall Street analyst predicted that BIO-RAD LABORATORIES's share price could reach $930.00 by Jul 30, 2022. The average BIO-RAD LABORATORIES stock price prediction forecasts a potential upside of 77.71% from the current BIO share price of $523.32.

What is BIO's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: BIO) BIO-RAD LABORATORIES's current Earnings Per Share (EPS) is -$3.07. On average, analysts forecast that BIO's EPS will be $14.20 for 2022, with the lowest EPS forecast at $14.20, and the highest EPS forecast at $14.20. On average, analysts forecast that BIO's EPS will be $15.65 for 2023, with the lowest EPS forecast at $15.65, and the highest EPS forecast at $15.65. In 2024, BIO's EPS is forecast to hit $17.87 (min: $17.87, max: $17.87).

What is BIO's forecast return on equity (ROE) for 2022-2024?

(NYSE: BIO) forecast ROE is 5.25%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.